Alnylam plans to make potential obesity debut by targeting specific gene

Boston-based biotech firm Alnylam has found a connection between a specific gene and abdominal fat, and is investigating possible candidates to target it.

Photo: Martin Havtorn Petersen/MedWatch

A month after getting a final approval for its candidate Amvuttra (vutrisan) to treat hATTR amyloidosis, US-based biotech firm Alnylam has revealed that it has more cards up its sleeve.

Endpointsnews reports that the firm is looking to enter the obesity market.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs